MRNA · Healthcare
What a holder would want to know before buying MRNA: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.
Today’s price is 906% above the lowest point of the past year and 0% below the highest.
Over the past year it was cheaper than today on more than 99% of days and more expensive on less than 1%. Over the last 8 years: cheaper on 93% of days.
210% above its average price of the last 200 trading days.
Fell 20% or more 8 times in 8 years. The deepest fall was 95%; the longest took 10 months to get back to its peak. 7 of 8 have recovered so far.
It is in one now: 54% below the Aug 2021 peak.
Moderna, Inc. · Healthcare · Biotechnology · a large company worth $89.83B
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal…
revenue profit
Sales of $1.92B in 2025, and a loss of $2.82B. Sales grew in 0 of the last 3 years.
Loses money on its sales at the moment.
Would need about 4.3 years of free cash flow to repay all its debt.
No price-to-earnings figure: the business has no profit to measure against.
A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.
Pays no dividend.
23 analysts: 5 say buy, 15 hold, 3 sell. Their average 12-month target is $122.67 (range $45.00–$200.00).
Insiders made 0 purchases and 10 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.
Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.
Poshkan is paper trading: real prices, virtual money. Buy MRNA with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.
Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.